Lilly In­dia en­ters au­toim­mune seg­ment with Olu­mi­ant

BioSpectrum (India) - - COMPANY NEWS -

Eli Lilly and Com­pany (In­dia) Pvt. Ltd. has an­nounced the launch of Olu­mi­ant (baric­i­tinib). This an­nounce­ment has marked the com­pany’s en­try into the au­toim­mune seg­ment in In­dia. Olu­mi­ant (baric­i­tinib) is a on­cedaily oral med­i­ca­tion for the treat­ment of adults with mod­er­ateto-se­vere ac­tive Rheuma­toid Arthri­tis who have re­sponded in­ad­e­quately to, or who are in­tol­er­ant to one or more dis­ease-mod­i­fy­ing anti-rheumatic drugs (DMARDs). Olu­mi­ant may be used as monother­apy or in com­bi­na­tion with methotrex­ate. Olu­mi­ant is ap­proved in more than 50 coun­tries across the world. De­spite the mul­ti­ple op­tions avail­able for Rheuma­toid Arthri­tis, there still ex­ists an un­met need. More than half of the pa­tients with mod­er­ateto-se­vere Rheuma­toid Arthri­tis do not ex­pe­ri­ence re­mis­sion through con­ven­tional DMARDs. In clin­i­cal stud­ies, Olu­mi­ant has demon­strated sta­tis­ti­cally sig­nif­i­cant im­prove­ments in a num­ber of out­come mea­sures in­clud­ing pa­tient re­ported out­comes at var­i­ous time points with rapid on­set of ac­tion and sus­tained ef­fi­cacy as well as su­pe­ri­or­ity to stan­dard of care at ACR 20 (Amer­i­can Col­lege of Rheuma­tol­ogy) and DAS (Dis­ease Ac­tiv­ity Score) 28 at 12 weeks.

Newspapers in English

Newspapers from India

© PressReader. All rights reserved.